Genflow Biosciences plc
GENF.L · LSE
6/30/2025 | 3/31/2025 | 12/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | – | – | – | £0 |
| - Cash | £0 | £0 | £0 | £0 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | – | – | – | £0 |
| Revenue | £0 | £0 | -£0 | -£0 |
| % Growth | 0% | 130.9% | -308.2% | – |
| Gross Profit | £0 | £0 | -£0 | -£0 |
| % Margin | 100% | 100% | 100% | 100.6% |
| EBITDA | -£0 | -£0 | -£0 | -£0 |
| % Margin | -300.7% | -300.7% | 134.1% | 1,012.5% |
| Net Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -300.9% | -300.9% | 134.2% | 1,038% |
| EPS Diluted | -0.001 | -0.001 | -0.002 | -0.003 |
| % Growth | 0% | 33.3% | 55.9% | – |
| Operating Cash Flow | -£0 | -£0 | -£0 | -£0 |
| Capital Expenditures | £0 | £0 | £0 | £0 |
| Free Cash Flow | -£0 | -£0 | -£0 | -£0 |